Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET- ImCheck Therapeutics announced today an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting ...

Title: In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines. Session Date and Time: Monday, June 2, 2025, 1:30 PM-4:30 PM CDT The full text of the ...

Full abstracts will be available on the ASCO website on May 22, 2025, at 5:00 pm ET. IMA203 is an autologous, engineered T-cell receptor T-cell therapy (TCR T) that targets PRAME, an intracellular ...

The results of the trial will be presented at the ASCO cancer congress tomorrow, and simultaneously published in The Lancet Oncology journal. The SYMPLIFY trial is one of two large-scale community ...

Fast forward to this year’s ASCO congress, and it seems TIGIT may be starting to bounce back. Roche has reported encouraging phase 1b/2 results with tiragolumab plus its PD-L1 inhibitor ...

Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held ...

In this press release, forward-looking statements include statements concerning the timing and content of Corcept’s presentation at ASCO and cortisol’s potential to treat patients with ovarian ...

Want to receive your badge in the mail before the Meeting? Register by the early registration deadline! The ASCO Annual Meeting is cashless! If you would like to register onsite at the meeting, please ...

Want to receive your badge in the mail before the Meeting? Register by the early registration deadline! The ASCO Annual Meeting is cashless! If you would like to register onsite at the meeting, please ...